Dr. Moskowitz announced the administrative move of the Office of 
Recombinant DNA Activities (ORDA) to the Office of the Director. 
He said this change was in line with other administrative changes 
that focused on issues of public policy and science policy within 
OD. Among these changes were the establishment of an Office of 
AIDS Research and Office of Human Genome Research within the 
Office of the Director. 
Dr. Moskowitz explained the organizational structure of the 
Office of Science Policy and Legislation which consists of the 
Division of Legislation, the Division of Planning and Evaluation, 
and the Science Policy Division in which ORDA is now located. 
The Science Policy Division deals with issues such as use of 
animals in research and animal welfare, fetal tissue research and 
use of fetal tissue for therapeutic purposes as well as 
tangential issues such as space medicine and the health of 
astronauts . 
Dr. Moskowitz said his Office was in the process of developing 
updated job descriptions for Dr. Gartland's position as well as 
ORDA senior staff and expected formal advertisements to go out 
within the next month or two. He urged the Committee to aid in 
this search and asked that recommendations be brought to his 
attention for input into the personnel channels. 
Dr. McGarrity announced that Dr. Gartland had left the Office of 
Recombinant DNA Activities to take a role in the extramural AIDS 
research program. He noted Dr. Gartland is known to many as 
"Mr. ORDA," and he stated he felt it appropriate to pay tribute 
to Dr. Gartland for his many years of dedication and service to 
the RAC. 
Dr. McGarrity gave a brief synopsis of Dr. Gartland's academic 
and professional background, noting that he had come to NIH in 
the early 1970s to work with Dr. DeWitt Stetten in setting up the 
NIGMS Human Genetics Program. He remarked that the success of 
this program was due in part to Dr. Gartland's efforts in cell 
banking, a procedure which pooled researchers' resources into a 
central repository for all researchers to draw upon. In 1976, 
Dr. Donald Fredrickson appointed Dr. Gartland to head the Office 
of Recombinant DNA Activities, and since then Dr. Gartland has 
served in this capacity, at times representing the directors of 
the NIH institutes as well as the Director of NIH. Dr. Gartland 
was appointed Chairman of the U.S. -Japan Cooperative Program on 
Recombinant DNA, and has acted as liaison to many other 
countries. Dr. McGarrity noted Dr. Gartland received the NIH 
Director's Award, the NIAID Director's Award, and, in 1985, was 
the recipient of the Special Recognition Award from the U.S. 
Public Health Service. 
Recombinant DNA Research, Volume 13 
[231] 
